← FDA DRUG APPROVALS

FDA NDA · NDA009818

KEMADRIN

Sponsor: MONARCH PHARMS

APPLICATION
NDA009818
TYPE
NDA
ORIGINAL APPROVAL
1955-07-27
LATEST ACTION
2011-07-01
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

KEMADRINDiscontinued
PROCYCLIDINE HYDROCHLORIDE 2MG · TABLET · ORAL
KEMADRINDiscontinued
PROCYCLIDINE HYDROCHLORIDE 5MG · TABLET · ORAL

Approval history

2011-07-01Labeling · Supplement 18 · standardLabelAP
1982-09-03Manufacturing (CMC) · Supplement 15 · standardAP
1980-02-19Manufacturing (CMC) · Supplement 13 · standardAP
1979-06-14Manufacturing (CMC) · Supplement 11 · standardAP
1978-04-10Manufacturing (CMC) · Supplement 9 · standardAP
1978-04-10Manufacturing (CMC) · Supplement 10 · standardAP
1977-02-09Manufacturing (CMC) · Supplement 8 · standardAP
1976-09-27Manufacturing (CMC) · Supplement 7 · standardAP
1974-11-25Manufacturing (CMC) · Supplement 6 · standardAP
1955-07-27Type 1 - New Molecular Entity · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →